Incretin-based anti-obesity therapies (e.g., GLP-1 receptor agonists such as semaglutide; dual GIP/GLP-1 agonists such as tirzepatide) improve adiposity, insulin resistance, and inflammatory profiles, providing a biologically plausible pathway for endometrial risk modification [69]. Here, GIP is linked to obesity disorder.